Background
Phase II, single-arm study. 51 patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL). PMBCL had historically been treated with R-CHOP followed by mediastinal radiation. DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin + rituximab) was tested as a potentially curative approach that could eliminate the need for radiotherapy and its long-term toxicities in young patients.
Interventions and follow up
Regimen: DA-EPOCH-R every 21d × 6–8 cycles (dose-adjusted etoposide/vincristine/doxorubicin CIV × 4d + cyclophosphamide day 5 + prednisone + rituximab), without mediastinal radiotherapy, in newly diagnosed PMBCL
Primary endpoint: Event-free survival
Median follow-up: 5 years
Primary endpoint: Event-free survival
Median follow-up: 5 years
Results
5-year EFS: 93%
5-year OS: 97%
CR rate: 96% (end-of-treatment PET-negative)
PET-positive after treatment: 4 patients (2 biopsy-negative, 2 declined biopsy) — none received RT; all remained in remission
5-year OS: 97%
CR rate: 96% (end-of-treatment PET-negative)
PET-positive after treatment: 4 patients (2 biopsy-negative, 2 declined biopsy) — none received RT; all remained in remission
Adverse events
Hematologic: Grade 4 neutropenia 100% (expected, dose-limiting); grade 3/4 thrombocytopenia 23.5%; febrile neutropenia 36.3%
Neurologic/other: Peripheral neuropathy grade ≥2 17.6%; no treatment-related deaths; no radiation-related secondary malignancies at 5-year follow-up
Neurologic/other: Peripheral neuropathy grade ≥2 17.6%; no treatment-related deaths; no radiation-related secondary malignancies at 5-year follow-up
Conclusions
DA-EPOCH-R achieved exceptional 5-year EFS (93%) and OS (97%) in PMBCL without routine mediastinal radiotherapy, establishing this as a preferred standard for young patients with PMBCL and avoiding long-term RT toxicities (breast cancer, coronary disease, hypothyroidism).
Key Limitations
Single-arm, single-institution Phase II with a small sample size (n=51), without randomized comparison to R-CHOP +/- radiotherapy. The subsequent multicenter IELSG-37 randomized trial showed mediastinal radiotherapy could be safely omitted in PET-negative patients but did not establish DA-EPOCH-R superiority over R-CHOP. Universal grade 4 neutropenia requires growth-factor support and intensive monitoring. Generalizability beyond expert centers is uncertain.
Clinical Context
DA-EPOCH-R is a widely used regimen for PMBCL; no FDA/EMA approval applies as it combines generic agents. ESMO guidance lists DA-EPOCH-R among preferred frontline options for PMBCL, allowing omission of consolidative radiotherapy in PET-negative patients. ASCO-endorsed practice supports response-adapted radiotherapy decisions following the IELSG-37 results.